Key result
ICD shocks occur in ~18% of octogenarians, happening earlier in those with NICM.
Why the study?
Older adults are underrepresented in ICD trials, necessitating evaluation of ICD use and outcomes in the aging population.
Observational (n=143)
No
In octogenarians, ICD therapies are relatively infrequent but occur well before observed mortality, with earlier shocks seen in those with non-ischemic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Should not yet change ICD decisions in octogenarians; leaves open etiology-specific outcome trials.
Background Implantable cardiac defibrillators (ICDs) are essential for preventing sudden cardiac death. Despite inclusion in national guidelines, older adults are often underrepresented in trials. Evaluating ICD use in the aging population, particularly with advancements in heart failure treatment, is crucial. Objective This study examines outcomes in octogenarians undergoing ICD implantation for primary and secondary prevention, focusing on ICD therapies and mortality timing. Methods A retrospective observational study at a single Canadian academic center included patients ≥80 years old at ICD implantation, excluding those with <30 days follow‐up. Data on demographics, comorbidities, mortality, and ICD therapies were collected from electronic medical records. Clinical frailty was assessed using the Dalhousie Clinical Frailty Scale. Results We identified 143 patients (mean age 82.6 ± 2.2 years, 14% female) from May 2015 to October 2023. ICDs were implanted for primary prevention in 63 patients (44%) and secondary prevention in 80 patients (56%). Thirty‐seven patients were excluded due to insufficient follow‐up. ICD therapies occurred in 30 patients (25%) through anti‐tachycardia pacing (ATP) and in 19 patients (18%) through shocks. The mean time to first ATP was 16.9 ± 21.0 months, and to first shock, 21.2 ± 23.6 months. Among 66 patients with mortality data, 19 (24%) died at 31.3 ± 30.4 months. Patients with non‐ischemic cardiomyopathy experienced earlier shocks (7.7 vs. 32.2 months, p < 0.05). Conclusion Elderly patients undergoing ICD implantation have multiple comorbidities and competing causes of mortality. Device use is overall infrequent but occurs well before observed mortality. Prospective clinical trials are needed to determine ICD benefits in this age cohort.
No takes yet. Share an insight, caveat, or question.
Stringer et al. (2025) conducted an observational in Primary and secondary prevention of sudden cardiac death (n=143). Implantable cardiac defibrillator (ICD) was evaluated on ICD therapies and mortality timing. In octogenarians undergoing ICD implantation, device therapies occurred in 25% for anti-tachycardia pacing and 18% for shocks, with earlier shocks seen in non-ischemic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: